Disturbance of EZH2 behaviours in cancer includes both gain-of-function and loss-of-function mutations in EZH2, overexpression of EZH2, mutations in the H3K27 demethylase UTX, and mutations in the SWI/SNF chromatin remodelling complex (see review by Kim and Roberts [180])—this is related to cancer initiation, metastasis, immunity, metabolism, and drug resistance (see review by Duan, Du, and Guo [181], Gan et al. [182], and Huang et al. [183]). This evidence concerns the gene SMARCA1 and cancer.